Moore Kuehn Encourages PSXP, BRPM, HFC, and ADMS Investors to Contact Law Firm
28. Oktober 2021 14:58 ET
|
Moore Kuehn
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
ADAMAS ALERT: Bragar Eagel & Squire, P.C. Announces Commencement of Tender Offer and Encourages Investors to Contact the Firm
27. Oktober 2021 12:36 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors of its investigation into whether the officers or...
ADAMAS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ADMS and Encourages Investors to Contact the Firm
14. Oktober 2021 15:32 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
04. Juni 2019 11:49 ET
|
Schall Law
LOS ANGELES, June 04, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
31. Mai 2019 11:45 ET
|
Schall Law
LOS ANGELES, May 31, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas...
Adamas Reports First Quarter 2019 Financial Results
09. Mai 2019 16:03 ET
|
Adamas Pharmaceuticals, Inc.
- First quarter net product sales of $11.7 million - GOCOVRI® total prescriptions grew to approximately 5,820 in Q1 2019 - Phase 3 study of ADS-5102 (GOCOVRI) in walking impairment in patients with...
Adamas Announces Data Presentations at the 71st American Academy of Neurology Annual Meeting
06. Mai 2019 21:39 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas to Announce First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019
02. Mai 2019 16:05 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 first quarter financial results on Thursday, May 9,...
Adamas to Present at Two Upcoming Investor Conferences
20. Februar 2019 16:50 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019
20. Februar 2019 16:49 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results on...